## **HEALTHY U** MEDICAID

## PRIOR AUTHORIZATION REQUEST FORM PRIMARY HYPEROXALURIA TYPE 1

For authorization, please answer each question and fax this form PLUS chart notes back to the Healthy U Prior Authorization Department at 801-213-1547.

Failure to submit clinical documentation to support this request will result in a dismissal of the request.

If you have prior authorization questions, please call for Pharmacy Customer Service for assistance at 833-981-0212

| Dis  | sclaimer: Prior authorization request for  | ms are subject to change in acco   | ordance v            | with Fede                | eral and State notice requirements.         |  |  |  |
|--|--|--|----------------------|--------------------------|---|--|--|--|
|  | ·  |  |                      |                          |   |  |  |  |
| Da   | te:  | Member Name:   |                      | ID#:                     | :   |  |  |  |
| DC   | OB: Gender:  |  | Physician:           |                          |   |  |  |  |
| Of   | Office Phone: Office Fax:  |  | Office Contact:      |                          |   |  |  |  |
| Height/Weight:   |  |  |                      | HCPCS Code:              |   |  |  |  |
| pro<br>rec<br>Pro<br>Ple   | ember must try formulary preferred dru<br>eferred products has not been successfu<br>ason for failure. Reasons for failure must<br>oduct being requested: ☐ Oxlumo™ (lun<br>ease note: the preferred medication will<br>osing/Frequency:   | l, you must submit which prefer<br>st meet the Health Plan medical<br>masiran), □ Rivfloza™ (nedosira            | red prod<br>necessit | lucts hav<br>ty criterio | e been tried, dates of treatment, and<br>a. |  |  |  |
| If the request is for reauthorization, proceed to reauthorization section. |  |  |                      |                          |   |  |  |  |
|  | Questions  |  | Yes                  | No                       | Comments/Notes                              |  |  |  |
| 1.   | Is the request made by, or in consul specializes in the treatment of prima (PH1)?  |  |                      |                          | -   |  |  |  |
|  | <ul> <li>Does the member have a diagnosis of the following:</li> <li>Metabolic testing shows elevate excretion persistently &gt; 0.7mm less than 6 years of age a urina ratio &gt; the ULN for the memberon Genetic testing confirms a mutaglyoxylate aminotransferase (A</li> </ul> | ed urinary oxalate ol/1.73m²/day OR for those ry oxalate/serum creatinine r's age ation in the alanine GXT) gene |                      |                          | Please provide documentation                |  |  |  |
| 3.   | Has the member received a liver tra  | nsplant?   |                      |                          |   |  |  |  |
| 4.   | Does the member have an estimate (eGFR) > 30mL/min/1.73m <sup>2</sup> ?  | d glomerular filtration rate   |                      |                          | Please provide documentation                |  |  |  |
| 5.   | Has the prescriber educated the me<br>avoiding oxalate rich foods (e.g. cho<br>vegetables, black teas, nuts, star fru  | colate, leafy green  |                      |                          | Please provide documentation                |  |  |  |
| 6.   | Has the member tried and failed, or contraindication/intolerance to, larghigh urinary output (> 3 L/day/1.73   | ge fluid intake resulting in a   |                      |                          | Please provide documentation                |  |  |  |

| confinhi<br>mag<br>8. Has<br>confi  | the member tried and failed, is currently taking, or has a traindication/intolerance to, calcium-oxalate crystallization bitors (e.g. potassium citrate-citric acid, orthophosphate, gnesium oxide)?  the member tried and failed, is currently taking, or has a traindication/intolerance to, pyridoxine (Vitamin B6) for ≥ 3 on this without a positive response (defined as a reduction of 19% in urinary oxalate excretion)? |  |  | Please provide documentation  Please provide documentation |  |  |  |  |
|---|--|--|--|--|--|--|--|--|
| REAUTHORIZATION   |  |  |  |  |  |  |  |  |
| 1. Is th  | e request for reauthorization of therapy?  |  |  |  |  |  |  |  |
| sign<br>for t   | the member had a positive response to therapy with a ificant reduction from baseline in urinary oxalate levels or chose <6 years of age a decrease in urinary oxalate/serum itinine ratio?   |  |  | Please provide documentation                               |  |  |  |  |
|   | the member experienced unacceptable drug toxicity to rapy?   |  |  |  |  |  |  |  |
| 4. Has  | the member received a liver transplant?  |  |  |  |  |  |  |  |
| What medications and/or treatment modalities have been tried in the past for this condition? Please document name of treatment, reason for failure, treatment dates, etc. |  |  |  |  |  |  |  |  |
|   | nal information:   |  |  |  |  |  |  |  |
| Physician Signature:  |  |  |  |  |  |  |  |  |

\*\* Failure to submit clinical documentation to support this request will result in a dismissal of the request.\*\*

Policy PHARM-HU-M035 Origination Date: 01/01/2022 Reviewed/Revised Date: 03/27/2024 Next Review Date: 03/27/2025 Current Effective Date: 04/01/2024

## **Confidentiality Notice**

This document and any accompanying document contain confidential information and is intended for the use of the individual or entity named on this transmission sheet. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or the taking of any action in reliance on the contents of this information is strictly prohibited and the document should be returned to this office immediately. If you have received this facsimile in error, please notify us by telephone immediately and destroy document received.